

ASX Announcement

31 August 2026

BOARD CHANGES

Genetic Signatures Limited (ASX: GSS) (“GSS” or “the Company”) today announced changes to the composition of its Board of Directors.

Ms Caroline Waldron has advised the Board of her decision to resign as Non-Executive Chair and Director of the Company, effective today. Mr Mike Aicher, an Executive Director of the Company since May 2014, will assume the role of Chair, ensuring continuity of Board leadership.

During Ms Waldron’s tenure as Chair, the Company has undertaken a comprehensive reset of its operating model and cost base, strengthened its footprint in EMEA, provided a clearly defined strategy for sustainable growth and refreshed its Board and executive leadership to deliver long-term value to its shareholders. Ms Waldron’s decision reflects her desire to devote greater time to her other professional commitments.

Chair, Mr Aicher, said: “On behalf of the Board and the Company, I thank Caroline for her steady and considered leadership through a formative period for Genetic Signatures. She leaves the Company in a strong financial position, with a clear strategic direction and a strengthened platform for growth.”

The Board is currently considering its composition in order to support the Company’s next phase of development and will make appropriate announcements in due course.

– END –

Announcement authorised by Genetic Signatures’ Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Mike Aicher

Chair

mike.aicher@geneticsignatures.com

T: +61 (0)2 9870 7580

About Genetic Signatures Limited:

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures’ proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.